Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer, according to a large randomized clinical trial conducted by researchers from SWOG Cancer Research Network.
The American Society of Clinical Oncology published new guidelines to support clinicians in managing immune-related adverse events in adult cancer patients treated with CAR T-cell therapy.
Researchers from the Gwangju Institute of Science and Technology have developed a deep learning model that predicts unexpected drug-drug interactions (DDIs) based on their effects on gene expression.Â
Breast cancer screening and early detection efforts have contributed to improved survival in recent decades, as breast cancer is more easily treated at early stages. But not all women have benefited equally.Â
A phase Ib study by MD Anderson researchers demonstrated that targeting angiogenesis drivers—such as delta-like ligand 4 (DLL4)—may improve responses to vascular endothelial growth factor (VEGF) inhibitors and may lead to improved outcomes in patients with platinum-resistant ovarian cancer (PROC).Â
Enhertu (fam-trastuzumab deruxtecan-nxki) received FDA regular approval for adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy.
FDA granted Priority Review for Imfinzi (durvalumab) in combination with standard-of-care chemotherapy, for patients with locally advanced or metastatic biliary tract cancer (BTC).
FDA granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation.Â
The European Commission approved Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.Â
The European Commission has approved the use of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy.Â
